Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Edoxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | F5 | P12259 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edoxaban SCHEMBL715418 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL330046 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL1504007 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL12320151 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL715737 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL1312016 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL715818 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL12833357 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL16436967 | 1.00 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL714523 | 1.00 | F10 (1.00) | F10F2F5PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | APOTEX INC. (CA) | 2019-05-28 | — | — | US | disclosed |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2018-06-28 | — | — | US | disclosed |
| US-20170354723-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | PROMETHERA BIOSCIENCES S.A. (BE) | 2017-12-14 | — | — | US | disclosed |
| US-9775890-B2 | Factor Xa inhibitor used with liver-derived progenitor cells | Université Catholique de Louvain (BE) | 2017-10-03 | — | — | US | disclosed |
| US-20150037291-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2015-02-05 | — | — | US | disclosed |
| EP-2444087-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED SOLUBILITY | Daiichi Sankyo Company, Limited (JP) | 2012-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354723-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | SERPINC1, F13B, F12 | F10 7/4885F2 9/4885F5 5/4885 |
| US-20150037291-A1 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | SERPINC1, F13B, F12 | F10 8/4885F2 10/4885F5 5/4885 |
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | VKORC1, CYP2C9, VKORC1L1 | F10 26/4885F2 23/4885F5 40/4885 |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | VKORC1, CYP2C9, VKORC1L1 | F10 26/4885F2 23/4885F5 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.